new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




  

Merrimack Pharmaceuticals Inc patents

Recent patent applications related to Merrimack Pharmaceuticals Inc. Merrimack Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Merrimack Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Merrimack Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "M" | Merrimack Pharmaceuticals Inc-related inventors




Date Merrimack Pharmaceuticals Inc patents (updated weekly) - BOOKMARK this page
04/27/17Compositions and methods for non-invasive imaging
04/13/17Biomarkers for predicting outcomes of cancer therapy with erbb3 inhibitors
04/06/17Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
03/23/17Liposomes useful for drug delivery
03/23/17Liposomes useful for drug delivery
03/23/17Liposomes useful for drug delivery
03/23/17Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
03/23/17Anti-c-met tandem fc bispecific antibodies
03/23/17Marker quantitation in single cells in tissue sections
03/16/17Liposomes useful for drug delivery
03/16/17Antibodies against the ectodomain of erbb3 and uses thereof
03/09/17Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
02/23/17Combination therapy for cancer treatment
02/23/17Methods for treating pancreatic cancer using combination therapies
02/23/17Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
02/23/17Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
02/09/17Liposomes useful for drug delivery to the brain
01/26/17Combination therapies for treating her2-positive cancers
12/29/16Methods for treating pancreatic cancer using combination therapies
12/01/16Treatment of breast cancer with liposomal irinotecan
11/24/16Liposomes useful for drug delivery
11/24/16Liposomes useful for drug delivery
11/10/16Combination therapies comprising anti-erbb3 agents
10/27/16Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies
10/20/16Combination treatments with seribantumab
10/20/16Liposomes useful for non-invasive imaging and drug delivery
09/01/16Combination therapy for treating her2-positive cancers
09/01/16Dosage and administration of anti-egfr therapeutics
08/11/16Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
06/30/16Methods and compositions for improving outcomes of liposomal chemotherapy
06/16/16Bi-specific fusion proteins
05/19/16Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
05/19/16Compositions and methods for delivering nucleic acid to a cell
05/05/16Cartilage-binding fusion proteins
05/05/16Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
04/21/16Liposomes useful for drug delivery
04/07/16Liposomes useful for drug delivery
04/07/16Liposomes useful for drug delivery
03/31/16Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
03/24/16Liposomes useful for drug delivery
03/24/16Monoclonal and oligoclonal anti-egfr antibodies for use in the treatment of tumors expressing predominantly high affinity egfr ligands or tumors expressing predominantly low affinity egfr ligands
03/17/16Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
03/10/16Methods and compositions for improving outcomes of liposomal chemotherapy
02/18/16Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
02/11/16Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents
02/11/16Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents
02/04/16Liposomes useful for drug delivery
02/04/16Liposomes useful for drug delivery
01/21/16Compositions and methods for treating osteolytic bone disorders
01/14/16Dosage and administration of anti-egfr therapeutics
01/07/16Antibodies against epidermal growth factor receptor (egfr) and uses thereof
12/31/15Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
12/31/15Antibodies against epidermal growth factor receptor (egfr) and uses thereof
12/24/15Antibodies against epidermal growth factor receptor (egfr) and uses thereof
12/24/15Antibodies against epidermal growth factor receptor (egfr) and uses thereof
12/24/15Antibodies against epidermal growth factor receptor (egfr) and uses thereof
12/17/15Methods for selecting therapeutics for treatment of her2+ cancers
11/19/15Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
08/20/15Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies
08/20/15Overcoming resistance to erbb pathway inhibitors
07/23/15Combination therapies comprising anti-erbb3 agents
07/09/15Human serum albumin linkers and conjugates thereof
07/02/15Liposomes useful for drug delivery
07/02/15Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
05/21/15Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics
Patent Packs
05/14/15Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
04/23/15Marker quantitation in single cells in tissue sections
04/02/15Compositions and methods for non-invasive imaging
10/09/14Anti-c-met tandem fc bispecific antibodies
10/02/14Tandem fc bispecific antibodies
09/04/14Anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers
08/21/14Antibodies against epidermal growth factor receptor (egfr) and uses thereof
08/21/14Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents
08/21/14Antibodies against the ectodomain of erbb3 and uses thereof
06/26/14Bi-specific fusion proteins
06/19/14Monoclonal and oligoclonal anti-egfr antibodies for use in the treatment of tumors expressing predominantly high affinity egfr ligands or tumors expressing predominantly low affinity egfr ligands
06/05/14Liposomes useful for drug delivery
05/15/14Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
05/08/14Liposomes useful for drug delivery to the brain
05/08/14Antibodies against epidermal growth factor receptor (egfr) and uses thereof
Patent Packs
05/08/14Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
03/20/14Combination therapies comprising anti-erbb3 agents
01/16/14Dosage and administration of bispecific scfv conjugates
09/12/13Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
07/18/13Bispecific binding agents for modulating biological activity
05/23/13Expression of secreted human alpha-fetoprotein in transgenic animals
02/07/13Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
12/06/12Monoclonal and oligoclonal anti-egfr antibodies for use in the treatment of tumors expressing predominantly high affinity egfr ligands or tumors expressing predominantly low affinity egfr ligands
10/25/12Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
10/11/12Expression of secreted human alpha-fetoprotein in transgenic animals
09/27/12Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
07/12/12Bispecific binding agents for modulating biological activity
04/12/12Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
01/05/12Human serum albumin linkers and conjugates thereof
12/01/11Bi-specific fusion proteins
06/30/11Methods and systems for predicting response of cells to a therapeutic agent
05/26/11Antibodies against erbb3 and uses thereof
05/26/11Using response surfaces for screening inhibitor combinations and digital processing methods
03/31/11Expression of secreted human alpha-fetoprotein in transgenic animals
02/03/11Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
11/26/09Antibodies against erbb3 and uses thereof
10/01/09Bispecific binding agents for modulating biological activity
07/16/09Bispecific binding agents for modulating biological activity
02/26/09Recombinant human alpha-fetoprotein as an immunosuppressive agent







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Merrimack Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Merrimack Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';